Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-FR Version v8-FR
Language French French
Date Updated 2019-08-12 2019-08-12
Drug Identification Number 02238682 02238682
Brand name PLAVIX PLAVIX
Common or Proper name Plavix 75mg Plavix 75mg
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients CLOPIDOGREL CLOPIDOGREL
Strength(s) 75MG 75MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging size 90 90
ATC code B01AC B01AC
ATC description ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2019-07-02 2019-07-02
Actual start date
Estimated end date 2019-08-23 2019-08-23
Actual end date 2019-08-08 2019-08-08
Shortage status Resolved Resolved
Company comments Supply delay- The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. Supply delay- The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.
Health Canada comments